Skip header and navigation

Refine By

46 records – page 1 of 5.

[99Tcm]MAG3 gamma camera nephrography in epidemic nephritis.

https://arctichealth.org/en/permalink/ahliterature227655
Source
Nucl Med Commun. 1991 Jan;12(1):15-25
Publication Type
Article
Date
Jan-1991
Author
R. Paul
H. Kiiliäinen
L. Tarssanen
M. Vorne
Author Affiliation
Department of Internal Medicine, Mikkeli Central Hospital, Finland.
Source
Nucl Med Commun. 1991 Jan;12(1):15-25
Date
Jan-1991
Language
English
Publication Type
Article
Keywords
Disease Outbreaks
Finland - epidemiology
Hemorrhagic Fever with Renal Syndrome - epidemiology - physiopathology
Humans
Liver - physiopathology
Oligopeptides - diagnostic use
Organotechnetium Compounds - diagnostic use
Radioisotope Renography
Technetium Tc 99m Mertiatide
Abstract
There is a lack of systematic nephrographic studies on epidemic nephritis (EN). We studied 10 patients with EN using [99Tcm]MAG3 gamma camera nephrography and followed up 9 of them 22-68 days later when they had clinically recovered. Variables for renal clearance of [99Tcm]MAG3 and the retention of radioactivity in the kidneys and blood were calculated. In all patients renal function was impaired acutely. There was marked reconstitution of renal function in the control studies. [99Tcm]MAG3 clearance was inversely related to serum creatinine. On visual inspection the nephrograms showed no focal changes. Nephrography was more sensitive than sonography at identifying renal impairment. [99Tcm]MAG3 nephrography is a sensitive method for identifying renal involvement and reconstitution of renal function in EN. It may be a valuable adjunct to the diagnostic arsenal, especially in nonendemic areas where EN occurs only sporadically and where there may be diagnostic uncertainty in patients presenting acutely with EN.
PubMed ID
1673780 View in PubMed
Less detail

[Biliary excretory function of the liver in petrochemical industry workers with chronic diseases of the biliary tracts].

https://arctichealth.org/en/permalink/ahliterature250948
Source
Gig Tr Prof Zabol. 1976 Jul;(7):23-7
Publication Type
Article
Date
Jul-1976

Canadian multicenter azidothymidine trial: AZT pharmacokinetics.

https://arctichealth.org/en/permalink/ahliterature227253
Source
J Acquir Immune Defic Syndr. 1991;4(9):865-70
Publication Type
Article
Date
1991
Author
S. Child
J. Montaner
C. Tsoukas
M. Fanning
T. Le
R A Wall
J. Ruedy
Author Affiliation
Department of Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Source
J Acquir Immune Defic Syndr. 1991;4(9):865-70
Date
1991
Language
English
Publication Type
Article
Keywords
Adult
Canada
HIV Infections - drug therapy - physiopathology
Homosexuality
Humans
Liver - physiopathology
Liver Function Tests
Male
Smoking
Zidovudine - pharmacokinetics - therapeutic use
Abstract
The study objective was to describe the pharmacokinetics of azidothymidine (AZT) in a large population of early, asymptomatic human immunodeficiency virus (HIV)-infected individuals. The study design was a multicenter, prospective, descriptive single-dose pharmacokinetic study. Each of 66 fasting, male, HIV-infected homosexuals older than 18 years of age and in CDC classifications II, III, and IVC2 received a single 400-mg oral dose of AZT with subsequent pharmacokinetic measurements performed during an 8-h period for AZT and its major metabolite, glucuronylazidothymidine (GAZT). Results were obtained in 65 patients (36 smokers, 29 nonsmokers), of whom 3 were noted to have hepatic dysfunction. In those with normal hepatic function, the following parameters were described: AZT, area under the curve (AUC) +/- SD, 9.9 +/- 5.7 microM.h, maximum concentration (Cmax) +/- SD, 7.3 +/- 4.7 microM; time to maximum concentration (Tmax) +/- SD, 0.93 +/- 0.42 h, and half-life (t1/2) +/- SD, 1.0 +/- 0.8 h. Corresponding values for GAZT were: AUC +/- SD 35.7 +/- 10.3 microM.h, Cmax +/- SD 21.3 +/- 7.3 microM, Tmax +/- SD 1.2 +/- 0.50 h, t1/2 +/- SD 0.98 +/- 0.62 h, No significant differences were found in comparisons of study site, CDC classification of disease, smokers versus nonsmokers, and in patients with hepatic dysfunction, although a higher AUC and earlier Cmax for AZT was noted in the latter group. It is concluded that AZT pharmacokinetics are similar in patients with early asymptomatic HIV disease when compared with previous reports in patients with later disease.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed ID
1895207 View in PubMed
Less detail

Cardiorespiratory fitness and adiposity in metabolically healthy overweight and obese youth.

https://arctichealth.org/en/permalink/ahliterature112804
Source
Pediatrics. 2013 Jul;132(1):e85-92
Publication Type
Article
Date
Jul-2013
Author
Martin Sénéchal
Brandy Wicklow
Kristy Wittmeier
Jacqueline Hay
Andrea C MacIntosh
Pinar Eskicioglu
Niranjan Venugopal
Jonathan M McGavock
Author Affiliation
Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada.
Source
Pediatrics. 2013 Jul;132(1):e85-92
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Adolescent
Body Composition
Body Fat Distribution
Body mass index
Cross-Sectional Studies
Energy Metabolism - physiology
Fatty Liver - physiopathology
Female
Health promotion
Humans
Male
Manitoba
Metabolic Syndrome X - diagnosis - physiopathology
Motor Activity - physiology
Obesity - physiopathology
Overweight - physiopathology
Phenotype
Physical Fitness - physiology
Reference Values
Risk factors
Abstract
Controversy exists surrounding the contribution of fitness and adiposity as determinants of the Metabolically Healthy Overweight(MHO) phenotype in youth. This study investigated the independent contribution of cardiorespiratory fitness and adiposity to the MHO phenotype among overweight and obese youth.
This cross-sectional study included 108 overweight and obese youth classified as MHO (no cardiometabolic risk factors) or non-MHO (=1 cardiometabolic risk factor), based on age- and gender specific cut-points for fasting glucose, triglycerides, high-density lipoprotein cholesterol, systolic and diastolic blood pressure, and hepaticsteatosis.
Twenty-five percent of overweight and obese youth were classified as MHO. This phenotype was associated with lower BMIz-score (BMI z-score: 1.8 ± 0.3 vs 2.1 ± 0.4, P = .02) and waist circumference (99.7 ± 13.2 vs 106.1 ± 13.7 cm, P = .04) compared with non-MHO youth. When matched for fitness level and stratified by BMI z-score (1.6 ± 0.3 vs 2.4 ± 0.2), the prevalence of MHO was four fold higher in the low BMI z-score group (27% vs 7%; P = .03).Multiple logistic regression analyses revealed that the best predictor of MHO was the absence of hepatic steatosis even after adjusting for waist circumference (odds ratio 0.57, 95% confidence interval 0.40–0.80) or BMI z-score (odds ratio 0.59, 95% confidence interval 0.43–0.80).
The MHO phenotype was present in 25% of overweight and obese youth and is strongly associated with lower levels of adiposity,and the absence of hepatic steatosis, but not with cardiorespiratory fitness.
PubMed ID
23796736 View in PubMed
Less detail

[Changes in the function of the stomach, pancreas and liver in children suffering from lambliasis of the bile ducts under the effect of furazolidone therapy]

https://arctichealth.org/en/permalink/ahliterature44786
Source
Pediatr Akus Ginekol. 1967 Mar-Apr;2:25-7
Publication Type
Article

[Clinical characteristics of acute hepatic dystrophy in viral hepatitis in infants during the 1st year of life]

https://arctichealth.org/en/permalink/ahliterature57151
Source
Pediatr Akus Ginekol. 1972 Mar-Apr;(2):23-4
Publication Type
Article

46 records – page 1 of 5.